Topline data expected in first quarter of 2026 Head-to-head studies of AL001 versus a marketed lithium carbonate product was conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy subjects ATLANTA , Nov. 19, 2025 /PRNewswire/ -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (" Alzamend "), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of... Read More

Session Topic is the I nnovation and Current Directions in Military Suicide Prevention, Research, and Programs Presentation Title is Quantitate Differences in Lithium Brain-to-Plasma Exposure in PTSD Subjects Between AL001 and Lithium Carbonate ATLANTA, July 28, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical company, focused on developing novel products for the... Read More

During the year ended April 30, 2025, net cash provided by financing activities was $10.4 million Stockholder equity of $4.0 million at April 30, 2025, including $3.9 million of cash In May 2025, Alzamend dosed the first patient for the healthy human patients for the AL001 “Lithium in Brain” Studies at Massachusetts General Hospital In June 2025, Alzamend completed the final closing of its $5 million private placement months... Read More

Capital Raised to Support Five Clinical Trials ATLANTA, June 16, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder (“ BD ”), major depressive disorder (“ MDD ”) and post-traumatic stress disorder (“ PTSD ”), today announced that it has... Read More

Topline data expected by year end Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy subjects ATLANTA, May 29, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s... Read More

Topline data expected by year end Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy subjects ATLANTA, May 19, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s... Read More

Topline data expected by year end Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy subjects ATLANTA, May 13, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s... Read More

ATLANTA, May 08, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc . (Nasdaq: ALZN) (“ Alzamend ” or the “ Company ”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder (“ BD ”), major depressive disorder (“ MDD ”) and post-traumatic stress disorder (“ PTSD ”), today announced that Alzamend’s board of directors approved a... Read More

Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy subjects ATLANTA, May 07, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”),... Read More

ATLANTA, March 25, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder (“ BD ”), major depressive disorder (“ MDD ”) and post-traumatic stress disorder (“ PTSD ”), today announced its plans to initiate a highly anticipated phase II clinical study... Read More

Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in MDD subjects ATLANTA, March 18, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical company... Read More

ATLANTA, March 11, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder (“ BD ”), major depressive disorder (“ MDD ”) and post-traumatic stress... Read More

ATLANTA, March 04, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder (“ BD ”), major depressive disorder (“ MDD ”) and post-traumatic stress... Read More

ATLANTA, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc . (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder (“ BD ”), major depressive disorder (“ MDD ”) and post-traumatic stress disorder (“ PTSD ”), today announced its plans to initiate the first of five highly anticipated phase... Read More

Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy, Alzheimer’s disease, BD, MDD, and PTSD subjects ATLANTA / Feb 19, 2025 / Business Wire / Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a... Read More

Company to report on progress with clinical trials to be initiated in 2025 and expected milestones ATLANTA / Jan 15, 2025 / Business Wire / Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical company, focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder (“ BD ”), major depressive disorder (“ MDD ”) and post-traumatic stress... Read More

Presentation Topic is the Pharmacokinetics of AL001, a Lithium Salicylate/L-Proline Co-crystal, as a Potentially Beneficial Lithium Sparing Treatment for Bipolar Disorder Type 1, Alzheimer’s Disease, Major Depressive Disorder and Post-Traumatic Stress Disorder ATLANTA / Dec 18, 2024 / Business Wire / Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical company, focused on developing novel... Read More

During the six months ended October 31, 2024, net cash provided by financing activities was $8.3 million Stockholder equity of $3.8 million at October 31, 2024, including $4.1 million of cash Strengthened balance sheet in preparation for five clinical trials to be initiated in 2025 ATLANTA / Dec 12, 2024 / Business Wire / Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical company, focused... Read More

Alzamend is developing AL001, a lithium product designed for enhanced safety and efficacy compared to currently available FDA-approved and marketed lithium therapies At a low dose, AL001 evidenced consistently higher lithium concentrations than lithium carbonate within critical brain regions comprising target tissue for efficacy, which may provide therapeutic benefits with less risk in multiple neurological disorders Data... Read More

Data confirm the positive topline results announced in June 2023 identifying a maximum tolerated dose as assessed by an independent safety review committee Identified dose is unlikely to require lithium therapeutic drug monitoring Data will guide upcoming “Lithium in Brain” Phase II clinical trials in partnership with Massachusetts General Hospital, which were announced in August 2024 ATLANTA / Oct 16, 2024 / Business Wire /... Read More

ATLANTA / Oct 15, 2024 / Business Wire / Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder (“ BD ”), major depressive disorder (“ MDD ”) and post-traumatic stress disorder (“ PTSD ”), today announced that it has received formal written notice from The Nasdaq Stock... Read More

Fireside conversation to take place on October 17, 2024, at 1:30 PM ET ATLANTA / Oct 10, 2024 / Business Wire / Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder (“ BD ”), major depressive disorder (“ MDD ”) and post-traumatic stress disorder (“ PTSD ”), today... Read More

Alzamend recently announced partnership with Massachusetts General Hospital for five phase II clinical trials of AL001, involving healthy human subjects and patients with Alzheimer’s, BD, MDD and PTSD Alzamend has executed an agreement to provide sufficient capital over the next 18 months to finance the initiation and progression of AL001 and ALZN002 clinical trials ATLANTA / Aug 26, 2024 / Business Wire / Alzamend Neuro,... Read More

Harvard University Associate Professor, Dr. Ovidiu Andronesi MD, PhD, will be the principal investigator of the study Head-to-head study of AL001 versus a marketed lithium carbonate product will be conducted; the goal is to compare lithium in human brain and brain structures to identify a potentially ideal dose of AL001 that is safe and effective as current products ATLANTA / Aug 19, 2024 / Business Wire / Alzamend Neuro,... Read More

Harvard University Associate Professor, Dr. Ovidiu Andronesi MD, PhD, will be the principal investigator of the study Head-to-head study of AL001 versus a marketed lithium carbonate product will be conducted; the goal is to compare lithium in human brain and brain structures to identify a potentially ideal dose of AL001 that... Read More

Harvard University Associate Professor, Dr. Ovidiu Andronesi MD, PhD, will be the principal investigator of the study Head-to-head study of AL001 versus a marketed lithium carbonate product will be conducted; the goal is to compare lithium in human brain and brain structures to identify a potentially ideal dose of AL001 that is safe and effective as current products ATLANTA / Aug 06, 2024 / Business Wire / Alzamend Neuro,... Read More

Harvard University Associate Professor, Dr. Ovidiu Andronesi MD, PhD, will be the principal investigator of the study Head-to-head study of AL001 versus a marketed lithium carbonate product will be conducted; the goal is to compare lithium in human brain and brain structures to identify a potentially ideal dose of AL001 that is safe and effective as current products ATLANTA / Aug 05, 2024 / Business Wire / Alzamend Neuro,... Read More

ATLANTA / Jul 31, 2024 / Business Wire / Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder (“ BD ”), major depressive disorder (“ MDD ”) and post-traumatic stress disorder (“ PTSD ”), today announced that it has received a notification letter (the “ Compliance Notice... Read More

ATLANTA / Jul 12, 2024 / Business Wire / Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ” or the “ Company ”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder (“ BD ”), major depressive disorder (“ MDD ”) and post-traumatic stress disorder (“ PTSD ”), today announced that Alzamend’s board of directors approved a... Read More

ATLANTA / May 22, 2024 / Business Wire / Alzamend Neuro, Inc . (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder (“ BD ”), major depressive disorder (“ MDD ”) and post-traumatic stress disorder (“ PTSD ”), announced today that the Nasdaq Hearings Panel (“ Panel ”) granted Alzamend’s... Read More

Investor had agreed to purchase up to $25 million of preferred shares Alzamend expects to use proceeds to further its clinical trials and working capital purposes ATLANTA / May 14, 2024 / Business Wire / Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder (“ BD ”), major... Read More

ATLANTA / May 09, 2024 / Business Wire / Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder (“ BD ”), major depressive disorder (“ MDD ”) and post-traumatic stress disorder (“ PTSD ”), announced today that it has entered into a Securities Purchase Agreement (the “... Read More

ATLANTA / May 07, 2024 / Business Wire / Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder (“ BD ”), major depressive disorder (“ MDD ”) and post-traumatic stress disorder (“ PTSD ”), announced today that it has terminated its “at-the-market” equity offering program... Read More

Alzamend’s recently completed Phase IIA study of AL001 in Alzheimer’s patients and healthy subjects showed a benign safety profile and identified a candidate dose that is unlikely to require therapeutic drug monitoring Safety aspects of AL001 development may qualify for a 505(b)(2) NDA pathway for FDA approval ATLANTA / Dec 11, 2023 / Business Wire / Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage... Read More

Alzamend’s recently completed Phase IIA study of AL001 in Alzheimer’s patients and healthy subjects showed a benign safety profile and identified a candidate dose that is unlikely to require therapeutic drug monitoring Safety aspects of AL001 development may qualify for a 505(b)(2) NDA pathway for FDA approval ATLANTA / Nov 20, 2023 / Business Wire / Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage... Read More

ATLANTA / Nov 16, 2023 / Business Wire / Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder (“ BD ”), major depressive disorder (“ MDD ”) and post-traumatic stress disorder (“ PTSD ”), today announced that it has received a notification letter (the “ Compliance... Read More

Alzamend’s recently completed Phase IIA Study of AL001 in Alzheimer’s patients and healthy subjects showed a benign safety profile and identified a candidate dose that is unlikely to require therapeutic drug monitoring Safety aspects of AL001 development may qualify for a 505(b)(2) NDA pathway for FDA approval ATLANTA / Nov 13, 2023 / Business Wire / Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage... Read More

ATLANTA / Oct 30, 2023 / Business Wire / Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ” or the “ Company ”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder (“ BD ”), major depressive disorder (“ MDD ”) and post-traumatic stress disorder (“ PTSD ”), today announced that Alzamend’s board of directors approved a... Read More

Safety aspects of AL001 development may qualify for a 505(b)(2) NDA pathway for FDA approval Alzamend recently completed a Phase IIA Study of AL001 in Alzheimer’s patients and healthy subjects showing a benign safety/ tolerability profile while characterizing dosing levels unlikely to require therapeutic drug monitoring ATLANTA / Oct 23, 2023 / Business Wire / Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a... Read More

Alzamend’s recently completed Phase IIA study of AL001 in Alzheimer’s patients and healthy subjects identified a candidate dose that is unlikely to require therapeutic drug monitoring Safety aspects of AL001 development may qualify for a Section (505)(b)(2) NDA pathway in support of FDA approval ATLANTA / Oct 02, 2023 / Business Wire / Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical... Read More

ATLANTA / Sep 22, 2023 / Business Wire / Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder (“ BD ”), major depressive disorder (“ MDD ”) and post-traumatic stress disorder (“ PTSD ”), today announced that it received notice from the Nasdaq Hearings Panel (the “... Read More

Safety aspects of AL001 development may qualify for (505)(b)(2) pathway for FDA approval Alzamend’s recently completed a Phase IIA Study of AL001 in Alzheimer’s and healthy patients that identified a candidate dose that is unlikely to require therapeutic drug monitoring ATLANTA / Aug 30, 2023 / Business Wire / Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical company focused on developing... Read More

Topline data identifies maximum tolerated dose from Phase IIA multiple ascending dose study as assessed by an independent safety review committee Identified dose is unlikely to require lithium therapeutic drug monitoring Alzamend plans two Phase II clinical trials to investigate the safety and efficacy of AL001 for patients with mild to moderate Alzheimer’s disease Investigational new drug applications to be filed for AL001... Read More

Panel to be held on Tuesday, June 20, 2023 at 2:00 PM ET ATLANTA / Jun 13, 2023 / Business Wire / Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder, major depressive disorder (“ MDD ”) and post-traumatic stress disorder (“ PTSD ”), today announced that CEO Stephan... Read More

Ault Alliance Congratulates Alzamend Neuro on This Important and Historic Milestone in Clinical Drug Discovery and Development LAS VEGAS / Apr 04, 2023 / Business Wire / Ault Alliance, Inc. (NYSE American: AULT), a diversified holding company (“ Ault Alliance ” or the “ Company ”), is proud to announce that Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”) has initiated its Phase I/IIA clinical trial for its... Read More

ATLANTA / Apr 03, 2023 / Business Wire / Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder, major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced the initiation of a phase I/IIA clinical trial for its immunotherapy vaccine... Read More

ATLANTA / Apr 03, 2023 / Business Wire / Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder, major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced receipt of a “Study May Proceed” letter from the U.S. Food and Drug... Read More

Topline data expected in June 2023 ATLANTA / Mar 22, 2023 / Business Wire / Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder, major depressive disorder (“ MDD ”) and post-traumatic stress disorder (“ PTSD ”), today announced the completion of the clinical... Read More

ATLANTA / Mar 16, 2023 / Business Wire / Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder, major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced financial results for the third quarter ended January 31, 2023 and provided an... Read More

Presentation on Thursday, February 2, 2023 at 10:30 a.m. ET ATLANTA / Jan 26, 2023 / Business Wire / Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder, major depressive disorder (“ MDD ”) and post-traumatic stress disorder (“ PTSD ”), today announced that it will be... Read More

Study to Assess the Safety, Tolerability, and Efficacy of Autologous Amyloid Beta Mutant Peptide-Pulsed Dendritic Cells (ALZN002) in Subjects With Mild-to-Moderate Dementia of the Alzheimer's Type Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder, major... Read More

Topline Data for Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s Expected in Second Quarter of 2023 Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder, major depressive disorder (“ MDD ”) and post-traumatic... Read More